Cymoplive reveals the cancer behaviour that existing screening systems miss.
Most drug discovery measures early response: growth inhibition, viability, and target engagement. But cancer doesn’t just respond. It adapts.
Resistance and relapse are driven by phenotypic plasticity — the dynamic ability of cancer cells to reconfigure under stress.
Cymoplive makes this adaptation visible.
By recreating structured, tissue-like environments and tracking behaviour in real time, we convert hidden adaptive escape into measurable, decision-ready insight, early in the drug development pipeline.
Cymoplive for Society
Reducing Animal Dependency
50–100 million animals are used globally in research each year. Cymoplive advances human-relevant models that reduce reliance on animal testing while improving translational accuracy. We deliver better science with fewer animals.
Improving Predictive Power
Most oncology therapies fail due to poor human predictivity. Cymoplive captures adaptive cancer behaviour earlier, thus helping prevent ineffective treatments from reaching patients. Smarter prediction means safer, faster progress.
Accelerating Assay Timelines
Traditional preclinical workflows are slow and iterative. Cymoplive enables earlier insight into resistance dynamics, reducing time spent advancing non-viable candidates. By minimising delays, we empower faster, more informed decisions.
Enabling a Circular Research Model
We promote sustainable innovation by reusing biological byproducts and minimising experimental waste. We are committed to science that respects resources.